Venetoclax: Everything You Need To Know
HealthTree Foundation for AML is hosting an informative virtual roundtable focused on venetoclax, a key drug used in the treatment of Acute Myeloid Leukemia (AML). This roundtable will cover what venetoclax is, how it treats AML and how it is dosed. Designed for both patients and caregivers, this roundtable will provide valuable insights and answer common questions about this important therapy. We will have a 15-minute Q&A with our 2 panelists at the end, so come prepared with all of your questions!
Mary introduces the agenda for the event and featured speakers Dr. Catherine Lai and Dr. Gabriel Mannis
Dr. Catherine Lai will answer the question "What is venetoclax and how does it work?"
Dr. Gabriel Mannis will answer the question "How is venetoclax dosed?"
Type your questions in the chat and we will answer them!
Mary Arnett
Mary joined HealthTree in 2022 as a part of HealthTree's team to help expand into all blood cancers. She now works as HealthTree's Volunteer & Community Outreach Manager, helping to engage and involve community members in HealthTree's mission. When she isn't working, she loves being the fun aunt to her 13 nieces and nephews, attending concerts, experimenting with new recipes in the kitchen, and traveling to explore new cities.
Catherine Lai, MD, MPH
Dr. Lai is an Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at University of Pennsylvania’s Perelman Center for Advanced Medicine. Board-certified in hematology, oncology and internal medicine, she specializes in detecting, monitoring, and treating acute leukemias and myeloid malignancies in adults. Dr. Lai's research focuses on novel therapeutics, designing and conducting clinical trials, and health outcomes for leukemia and myeloid malignancy patients.
Gabriel Mannis, MD
Dr. Mannis is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, and Medical Director of Stanford’s Inpatient Leukemia Service. He specializes in the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. As a clinical scientist, Dr. Mannis divides his time between caring for patients, teaching trainees, and researching novel therapies for AML and MDS.